TargetBeta
EGFR
epidermal growth factor receptor · also ERBB1, ERRP, ERBB · Erb-b2 receptor tyrosine kinases
59 programs in company-led studies act on EGFR, from 46 companies: 24 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (46 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| osimertinibrule | AstraZeneca | phase 4 | 4215 running | – | NCIt |
| Panitumumabrule | Amgen | phase 4 | 433 running | – | NCIt |
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 5555 running | ERBB3 | a judged reading |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 1616 running | – | a judged reading |
| Cetuximabrule | Eli Lilly | phase 3 | 9013 running | – | NCIt |
| amivantamabrule | Johnson & Johnson | phase 3 | 1613 running | MET | NCIt |
| aflutinibrule | Allist Pharmaceuticals | phase 3 | 2111 running | – | NCIt |
| andamertinibrule | Avistone Biotechnology | phase 3 | 109 running | – | NCIt |
| pimurutamab | Fosun Pharma | phase 3 | 178 running | – | a judged reading |
| aumolertinibrule | Hansoh Pharmaceutical Group | phase 3 | 158 running | – | NCIt |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 118 running | – | a judged reading |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 77 running | – | the company's pipeline |
| lazertinibrule | Johnson & Johnson | phase 3 | 186 running | – | NCIt |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 125 running | ERBB2 | NCIt |
| becotatug vedotinrule | Lepu Biopharma | phase 3 | 105 running | – | NCIt |
| petosemtamabrule | Genmab | phase 3 | 65 running | LGR5 | NCIt |
| bafisontamabrule | Shanghai EpimAb Biotherapeutics | phase 3 | 54 running | MET | NCIt |
| zipalertinibrule | Otsuka | phase 3 | 44 running | – | NCIt |
| ficerafusp alfarule | Bicara Therapeutics | phase 3 | 33 running | TGFB1 | NCIt |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 33 running | MET | the company's pipeline |
| sevabertinibrule | Bayer | phase 3 | 82 running | ERBB2 | NCIt |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 62 running | – | NCIt |
| ASK-120067rule | Beijing Aosaikang Pharmaceutical | phase 3 | 52 running | – | the studies' text |
| zorifertinibrule | Alpha Biopharma (Jiangsu) | phase 3 | 41 running | – | NCIt |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | TJ Biopharma | phase 3 | 31 running | CD276 | NCIt |
| FHND-9041 | Sino Biopharmaceutical | phase 3 | 11 running | – | the company's pipeline |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 55 running | MET | the company's pipeline |
| silevertinibrule | Ryvu Therapeutics | phase 2 | 74 running | – | NCIt |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 54 running | MET | NCIt |
| EGFR Mutant-specific Inhibitor DZD6008rule | Dizal Pharmaceuticals | phase 2 | 33 running | – | NCIt |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 33 running | MET | the company's pipeline |
| enozertinibrule | ORIC Pharmaceuticals | phase 2 | 32 running | ERBB2 | NCIt |
| BEBT-109rule | BeBetter Med | phase 2 | 22 running | – | the studies' text |
| EGFR/EGFRvIII Inhibitor WSD0922-FUrule | Wayshine Biopharm | phase 2 | 22 running | – | NCIt |
| Staphylococcus epidermidis Strain Topical Ointment ATR04-484rule | Azitra | phase 2 | 21 running | – | NCIt |
| VRN110755rule | Voronoi | phase 2 | 21 running | – | the studies' text |
| Anti-EGFR Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A580rule | HUTCHMED | phase 2 | 11 running | – | NCIt |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 11 running | MET | NCIt |
| Anti-EGFR/Anti-CDCP1-MMAE Antibody-Drug Conjugate IDP-001rule | InduPro | phase 2 | 11 running | CDCP1 | NCIt |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | Avenzo Therapeutics | phase 2 | 11 running | ERBB3 | NCIt |
| EGFR/HER2 Mutant-selective Inhibitor BH-30643rule | BlossomHill Therapeutics | phase 2 | 11 running | ERBB2 | NCIt |
| KY-0301rule | Novatim Immune Therapeutics (Zhejiang) | phase 2 | 11 running | – | the studies' text |
| VBC117rule | VelaVigo Cayman | phase 2 | 11 running | – | the studies' text |
| YH32364rule | Yuhan | phase 2 | 11 running | – | the studies' text |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | Tavotek Biotherapeutics | phase 1 | 22 running | MET, VEGFA | NCIt |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 22 running | MET | the company's pipeline |
| Anti-EGFR Bispecific Antibody EPI-326rule | EpiBiologics | phase 1 | 11 running | – | NCIt |
| Anti-EGFR/Anti-MUC1 Bispecific Antibody-drug Conjugate NEOK002rule | NEOK Bio | phase 1 | 11 running | MUC1 | NCIt |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 11 running | MET | a judged reading |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 11 running | MET | NCIt |
| Anti-EGFR/CD3 Protease-activated T-cell Engager VIR-5525rule | Vir Biotechnology | phase 1 | 11 running | – | NCIt |
| Anti-EGFR/Top1i ADC ALX2004rule | ALX Oncology | phase 1 | 11 running | – | NCIt |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 11 running | ERBB3 | the studies' text |
| GENSCI139rule | Changchun GeneScience Pharmaceutical | phase 1 | 11 running | ERBB2 | the studies' text |
| HLX48 | Fosun Pharma | phase 1 | 11 running | MET | the company's pipeline |
| KGX105rule | Kangabio AUSTRALIA LTD PTY | phase 1 | 11 running | CD3E | the studies' text |
| MTX-531rule | MEKanistic Therapeutics | phase 1 | 11 running | – | the studies' text |
| TQB3002 | Sino Biopharmaceutical | phase 1 | 11 running | – | the company's pipeline |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | Outpace Bio | phase 1 | 10 running | IL2, MSLN | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 32 programs
- Squamous Cell Carcinoma of Head and Neck, 10 programs
- Colorectal Neoplasms, 8 programs
- Lung Neoplasms, 7 programs
- Neoplasms, 5 programs
- Breast Neoplasms, 4 programs
- Neoplasm Metastasis, 4 programs
- Nasopharyngeal Carcinoma, 3 programs
- Stomach Neoplasms, 3 programs
- Carcinoma, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026izalontamab brengitecan · Sichuan Biokin Pharmaceutical · phase 3 · NCT06118333
- Nov 2026andamertinib · Avistone Biotechnology · phase 3 · NCT07336732
- Nov 19, 2026HS-10504 · Hansoh Pharmaceutical Group · phase 3 · NCT07685041
- Nov 30, 2026Anti-EGFR Antibody-drug Conjugate CPO301 · CSPC Pharmaceutical Group · phase 3 · NCT07256509
- Dec 2026aflutinib · Allist Pharmaceuticals · phase 3 · NCT04853342
- Dec 2026TQB2922 · Sino Biopharmaceutical · phase 2 · NCT06188624
- Dec 2026silevertinib · Ryvu Therapeutics · phase 2 · NCT06987058
- Dec 2026enozertinib · ORIC Pharmaceuticals · phase 2 · NCT06816992
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.